Welcome to our dedicated page for Relief Hldg news (Ticker: RLFTF), a resource for investors and traders seeking the latest updates and insights on Relief Hldg stock.
Relief Therapeutics Holding SA (OTCQB: RLFTF), historically known as Relief Therapeutics, regularly issues news updates covering its biopharmaceutical pipeline, corporate milestones, and, more recently, its transformation into MindMaze Therapeutics Holding SA through a business combination with NeuroX Group SA. Company press releases describe a focus on rare dermatological, metabolic, and respiratory diseases, along with digital neurotherapeutics and an AI-powered brain health platform following the combination.
News items for RLFTF include clinical and regulatory developments such as FDA designations and meeting outcomes for RLF-TD011 in epidermolysis bullosa, and pivotal bioequivalence study results for RLF-OD032, a liquid sapropterin formulation for phenylketonuria. Investors and observers can also find updates on corporate governance events like annual general meetings, half-year and annual report publications, and shareholder approvals for strategic transactions.
Coverage further extends to transaction-related announcements, including the proposed and completed business combination with NeuroX, details on share exchanges, and the renaming of the company to MindMaze Therapeutics Holding SA. Subsequent communications describe the combined company’s activities in digital neurorehabilitation and neurological care, while noting that it continues to manage Relief’s preexisting biopharmaceutical assets.
By following RLFTF news, readers can track the evolution of Relief’s rare disease programs, its regulatory interactions, and the integration of its portfolio into the broader MindMaze Therapeutics platform. This news stream provides context on how the company positions its therapies and digital technologies within the rare disease and neurology landscapes.
Relief Therapeutics has announced a strategic update concerning its financing efforts, opting to withdraw a prior SEC registration statement to explore non-dilutive funding options. This move aims to facilitate a potential listing on the Nasdaq. The company plans a reverse stock split, pending shareholder approval, to enhance its appeal to investors. The proposed reverse split is part of a broader initiative to improve the company's public perception and reduce the number of outstanding shares, which currently stems from past mergers. Relief is focused on treating rare diseases and aims to advance its innovative pipeline, including partnerships for metabolic disorder treatments.
Relief Therapeutics Holding announced independent IRB approval for a trial of RLF-TD011 as an adjunctive treatment for cutaneous T-cell lymphoma (CTCL). This proof-of-concept study, led by Dr. Alan Zhou at Northwestern University, aims to assess the effects of RLF-TD011, a hypochlorous acid topical spray, on CTCL lesions over an eight-week period with 30 participants. Given the challenging prognosis of CTCL, where advanced cases have a five-year survival rate of just 24%, this study represents a critical development pathway for RLF-TD011, with potential implications for FDA and EMA submissions for this unmet medical need.
Relief Therapeutics Holding SA has filed Amendment No. 2 to its Registration Statement on Form F-1 with the SEC, proposing an offering of up to 833,333,200 ordinary shares as American Depositary Shares (ADSs). The preliminary prospectus includes warrants for an additional 625,000,000 shares. Underwriters may also purchase an extra 125,000,000 shares and warrants. The terms of the offering remain uncertain, pending finalization in a future amendment. The effectiveness of the registration statement and completion of the offering are not guaranteed, affecting potential investor interest.
Relief Therapeutics and NRx Pharmaceuticals have finalized settlement agreements resolving litigation between them. Key outcomes include Relief acquiring all assets related to the aviptadil development program, including regulatory filings and clinical data. Relief will now exclusively develop and commercialize aviptadil, continuing its Right to Try Program for two years. Moreover, Relief will make milestone payments to NeuroRx for commercial approval and pay royalties, capped at $30 million. The companies have agreed not to compete in aviptadil development.
Relief Therapeutics Holding SA will present at the 15th Annual Biotech Showcase and host investor meetings on January 9-10, 2023, in San Francisco. CEO Jack Weinstein will provide insights into the company’s rare disease portfolio and commercial strategy. The Biotech Showcase presentation is scheduled for January 10 at 3:30 PM PST. The company focuses on developing novel treatments for rare diseases and holds a diverse pipeline, including products for phenylketonuria and epidermolysis bullosa.
Relief Therapeutics Holding SA has announced an increase in its share capital from 4.62 billion to 5.62 billion shares by issuing 1 billion new shares, fully subscribed by its subsidiary, Relief Therapeutics International SA. These new shares will be listed on the SIX Swiss Exchange around December 22, 2022. Following this issuance, Relief expects about 1.2 billion shares to be held in treasury for future financing transactions, while the outstanding shares will remain unchanged until placement.
Relief Therapeutics announces leadership changes with Jack Weinstein appointed as CEO and Jeremy Meinen as CFO. Effective immediately, Weinstein aims to enhance the company's long-term strategy following the launch of their first product, PKU GOLIKE. Meinen, who has been with Relief since 2020, now takes on more responsibility in driving financial growth. These appointments come after the settlement of litigation with NRx Pharmaceuticals, signaling a strategic shift for Relief to focus on expanding its operations in the biopharmaceutical sector.
Relief Therapeutics announced the filing of Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. SEC for a proposed offering of ordinary shares in the form of American Depositary Shares (ADSs). Details regarding the number and pricing of the ADSs are yet to be determined. The company plans to list these ADSs on the NASDAQ under the symbol RLFT. The offering will only proceed with an effective prospectus.
Relief Therapeutics Holding SA and NRx Pharmaceuticals have reached settlement agreements to resolve litigation. Within the next 30 days, NRx will transfer assets used in aviptadil development to Relief. Relief will gain exclusive rights to develop and commercialize aviptadil while continuing the Right to Try Program for two years. They will pay NRx milestone payments for successful product approvals and royalties up to $30 million based on sales. NRx will refrain from future competition in aviptadil development. The success of aviptadil commercialization is uncertain.
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. have extended the stay of their pending litigation until November 11, 2022. They are progressing in negotiations for a settlement; however, no final agreements have been reached, introducing uncertainty about the outcome.
Relief specializes in developing treatments for rare diseases, with products including PKU GOLIKE and ongoing projects like aviptadil and APR-TD011, which has FDA Orphan Drug Designation. The company is listed on the SIX Swiss Exchange under symbol RLF and OTCQB under RLFTF and RLFTD.